Tagami T, Gu W X, Peairs P T, West B L, Jameson J L
Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Mol Endocrinol. 1998 Dec;12(12):1888-902. doi: 10.1210/mend.12.12.0201.
In a patient with severe resistance to thyroid hormone (RTH), we found a novel mutation (leucine to serine in codon 454, L454S) of the thyroid hormone receptor beta. This mutation is in the ligand-dependent transactivation domain that has been shown to interact with transcriptional coactivators (CoAs). The mutant protein binds T3, but its ability to activate transcription of a positively regulated gene (TRE-tk-Luc), and to repress a negatively regulated gene (TSHalpha-Luc), is markedly impaired. As anticipated from its location, the L454S mutant interacts weakly with CoAs, such as SRC1 and glucocorticoid receptor interacting protein 1 (GRIP1) in gel mobility shift assays and in mammalian two-hybrid assays, even in the presence of the maximal dose of T3. In contrast, in the absence of T3, the L454S mutant interacts much more strongly with nuclear receptor corepressor (NCoR) than does the wild-type receptor, and the T3-dependent release of NCoR is markedly impaired. By comparison, the NCoR interaction and T3-dependent dissociation of an adjacent AF-2 domain mutant (E457A) are normal. These findings reveal that the Leu 454 is involved directly, or indirectly, in the release of corepressors (CoRs) as well as in the recruitment of CoAs. The strong interaction with NCoR at a physiological concentration of T3 results in constitutive activation of the TSH genes as well as constitutive silencing of positively regulated genes. When the dominant negative effect was examined among various mutants, it correlated surprisingly well with the potency of NCoR binding but not with the degree of impairment in CoA binding. These findings suggest that the defective release of NCoRs, along with retained dimerization and DNA binding, are critical features for the inhibitory action of mutant thyroid hormone receptors. These studies also suggest that helix 12 of the thyroid hormone receptor acts as a dual functional domain. After the binding of T3, its conformation changes, causing the disruption of CoR binding and the recruitment of CoAs.
在一名严重甲状腺激素抵抗(RTH)患者中,我们发现了甲状腺激素受体β的一种新突变(密码子454处的亮氨酸突变为丝氨酸,L454S)。该突变位于配体依赖性反式激活结构域,该结构域已被证明可与转录共激活因子(CoAs)相互作用。突变蛋白能结合T3,但其激活正向调控基因(TRE-tk-Luc)转录以及抑制负向调控基因(TSHα-Luc)转录的能力明显受损。正如从其位置所预期的那样,在凝胶迁移率变动分析和哺乳动物双杂交分析中,即使存在最大剂量的T3,L454S突变体与CoAs(如SRC1和糖皮质激素受体相互作用蛋白1,GRIP1)的相互作用也很弱。相比之下,在没有T3的情况下,L454S突变体与核受体共抑制因子(NCoR)的相互作用比野生型受体更强,并且NCoR的T3依赖性释放明显受损。相比之下,相邻AF-2结构域突变体(E457A)的NCoR相互作用和T3依赖性解离是正常的。这些发现表明,亮氨酸454直接或间接参与共抑制因子(CoRs)的释放以及共激活因子(CoAs)的募集。在生理浓度的T3下与NCoR的强相互作用导致TSH基因的组成性激活以及正向调控基因的组成性沉默。当在各种突变体中检测显性负效应时,它与NCoR结合的效力惊人地良好相关,但与CoA结合的受损程度无关。这些发现表明,NCoRs的缺陷性释放以及保留的二聚化和DNA结合是突变甲状腺激素受体抑制作用的关键特征。这些研究还表明,甲状腺激素受体的螺旋12作为一个双功能结构域。T3结合后,其构象发生变化,导致CoR结合的破坏和CoAs的募集。